Project cooperationUpdated on 11 December 2025
Human Phenotype Project Data for Personalized Medicine Approaches
Medical Advisor at Weizmann Institute of Science
Rehovot, Israel
About
Prof. Eran Segal's gropup at the Weizmann Institute of Sciuence develop a robust and generalizable artificial intelligence (AI) models that can leverage multimodel data of the Human Phenotype Project (HPP) and other data sources for biomedical research in the field of metabolic and cardiovascular diseases and sleep medicine. We have established the HPP, a large-scale deep-phenotype prospective longitudinal cohort with >13,000 participants to date, aimed at identifying novel molecular markers with diagnostic, prognostic and therapeutic value, and at developing prediction models for disease onset and progression. Included in the cohort are ~7,700 people with 40 diseases such as metabolic diseases, neurological disorders, and cardiovascular disease, where some people have multiple comorbidities. For each participant, their deep phenotype profile consists of diverse modalities, including imaging (e.g., ultrasound, retina scans), time-series (e.g., electrocardiogram; ECG, continuous glucose monitor‐ing; CGM and sleep), multi-omics (e.g., transcriptome, genetics, microbiome, metabolome), tabular (blood tests, body measures), and ques‐tionnaire and APP data types (e.g., lifestyle and nutritional habits). Repeated measures are collected every two years. Collectively, this rich and heterogeneous dataset represents a unique opportunity for developing and validating foundation AI models that can transform the biomedical field. We are also open to partnering with other project that benefit from the HPP data and advanced computational capabilities
Topic
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Type
- Partner seeks Consortium/Coordinator
Similar opportunities
Project cooperation
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
Fiona Bedford
Scientific Advisor at Weizmann Institute of Sciences
Rehovet, Israel
Project cooperation
Cardiovascular risk and mitochondrial dysfunction in liver diseases
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
Maria J Sanchez Quintero
Senior Researcher at Biomedical Research Institute of Málaga
Málaga, Spain
Project cooperation
Insulin and IGF Signalling Mechanisms in Metabolic, Cardiovascular and Cancer Diseases
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
Jiri Jiracek
group leader at IOCB Prague
Praha, Czech Republic